Evaluating the effects of antihistamines and amantadine on COVID-19 outcomes
Evaluation of Treatments With Antihistamines and Amantadine in the Evolution of the SARS-CoV-2 Infection
This study is testing whether taking antihistamines or amantadine helps older patients in nursing homes have better outcomes with COVID-19 compared to those who don't take these medications.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 140660 (estimated) |
| Sex | All |
| Sponsor | Consorci Sanitari de Terrassa Academic / other |
| Locations | 2 sites (Terrassa, Barcelona and 1 other locations) |
| Trial ID | NCT05504057 on ClinicalTrials.gov |
What this trial studies
This observational study aims to quantify the rates of symptomatic COVID-19 infection, hospital admissions, and survival among patients who are chronically treated with antihistamines or amantadine. The research will analyze data from patients in nursing homes and compare their outcomes with a control group from the Terrassa Health Consortium. By stratifying results by age groups, the study seeks to determine the potential protective roles of these medications in the evolution of COVID-19.
Who should consider this trial
Good fit: Ideal candidates for this study are patients who are on chronic treatment with antihistamines or amantadine.
Not a fit: Patients not receiving chronic treatment with antihistamines or amantadine may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could identify effective treatments that improve outcomes for COVID-19 patients.
How similar studies have performed: Previous reports have suggested potential benefits of antihistamines and amantadine in COVID-19 cases, indicating that this approach may have merit.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: Patients having chronic treatment with antihistamines or amantadine - Exclusion Criteria: None \-
Where this trial is running
Terrassa, Barcelona and 1 other locations
- Hospital de Terrassa — Terrassa, Barcelona, Spain (Recruiting)
- Hospital of Terrassa — Terrassa, Barcelona, Spain (Recruiting)
Study contacts
- Principal investigator: Anna Puigdellívol, PhD — Terrassa Health Consortium
- Study coordinator: Anna Puigdellivol, Ph.D
- Email: apuigdellivol@cst.cat
- Phone: 34-93-5884555
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.